1. Allogeneic Hematopoietic Cell Transplantation in Patients Age Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine 
Uwe Platzbecker, Johannes Schetelig, Jürgen Finke, Rudolf Trenschel, Bart L. Scott, Guido Kobbe, Kerstin Schaefer-Eckart, Martin Bornhäuser, Raphael Itzykson, Ulrich Germing, Dietrich Beelen, Gerhard Ehninger, Pierre Fenaux, H. Joachim Deeg, Lionel Adès 
Biology of Blood and Marrow Transplantation 
Volume 18, Issue 9, Pages (September 2012)
DOI: /j.bbmt
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
OS and EFS among patients with MDS followed from the start of therapy according to treatment approach.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Stacked cumulative incidence curves from a competing-risks model with relapse and death as competing risks, with the study population substratified according to type of treatment: (A) AZA, (B) HCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions